NCT04989725View on ClinicalTrials.gov

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Head and Neck CancerMetastatic CancerOligoprogressive
Interventions
OTHER

Standard arm

Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.

RADIATION

Experimental arm

SABR to all oligoprogressive lesions + continuation of current systemic therapy

Trial Locations (1)

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER